Yousif Capital Management LLC Lowers Stock Holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB)

Yousif Capital Management LLC reduced its stake in Mesa Laboratories, Inc. (NASDAQ:MLABFree Report) by 6.1% during the 3rd quarter, HoldingsChannel reports. The firm owned 2,553 shares of the medical instruments supplier’s stock after selling 165 shares during the period. Yousif Capital Management LLC’s holdings in Mesa Laboratories were worth $268,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Point72 Hong Kong Ltd purchased a new position in shares of Mesa Laboratories in the 1st quarter valued at approximately $27,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new position in shares of Mesa Laboratories in the 2nd quarter valued at approximately $41,000. Tower Research Capital LLC TRC grew its stake in shares of Mesa Laboratories by 235.2% in the 1st quarter. Tower Research Capital LLC TRC now owns 295 shares of the medical instruments supplier’s stock valued at $52,000 after purchasing an additional 207 shares during the last quarter. Amundi purchased a new position in shares of Mesa Laboratories in the 4th quarter valued at approximately $102,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Mesa Laboratories in the 3rd quarter valued at approximately $112,000. 91.06% of the stock is currently owned by hedge funds and other institutional investors.

Mesa Laboratories Stock Down 2.6 %

Shares of NASDAQ:MLAB opened at $91.62 on Thursday. Mesa Laboratories, Inc. has a 12-month low of $82.86 and a 12-month high of $206.36. The company has a fifty day simple moving average of $98.30 and a 200 day simple moving average of $109.45. The company has a current ratio of 2.96, a quick ratio of 2.13 and a debt-to-equity ratio of 0.44. The firm has a market cap of $493.83 million, a PE ratio of -654.38 and a beta of 0.81.

Mesa Laboratories (NASDAQ:MLABGet Free Report) last posted its quarterly earnings results on Monday, November 6th. The medical instruments supplier reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.22. Mesa Laboratories had a positive return on equity of 8.17% and a negative net margin of 0.34%. The company had revenue of $53.17 million for the quarter, compared to analysts’ expectations of $54.65 million. On average, equities research analysts anticipate that Mesa Laboratories, Inc. will post 5.56 EPS for the current fiscal year.

Mesa Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 15th. Investors of record on Thursday, February 29th will be issued a dividend of $0.16 per share. The ex-dividend date of this dividend is Wednesday, February 28th. This represents a $0.64 dividend on an annualized basis and a yield of 0.70%. Mesa Laboratories’s dividend payout ratio is -457.11%.

Analyst Ratings Changes

A number of research firms recently weighed in on MLAB. began coverage on Mesa Laboratories in a research note on Thursday, October 5th. They issued a “hold” rating on the stock. Evercore ISI upgraded shares of Mesa Laboratories from an “in-line” rating to an “outperform” rating and raised their target price for the company from $100.00 to $125.00 in a report on Thursday, January 4th.

Read Our Latest Research Report on MLAB

Insider Buying and Selling

In related news, SVP Brian David Archbold sold 1,500 shares of the firm’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $112.36, for a total value of $168,540.00. Following the completion of the transaction, the senior vice president now directly owns 558 shares of the company’s stock, valued at $62,696.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 5.20% of the stock is owned by insiders.

Mesa Laboratories Profile

(Free Report)

Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions.

Further Reading

Want to see what other hedge funds are holding MLAB? Visit to get the latest 13F filings and insider trades for Mesa Laboratories, Inc. (NASDAQ:MLABFree Report).

Institutional Ownership by Quarter for Mesa Laboratories (NASDAQ:MLAB)

Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with's FREE daily email newsletter.